SHENYANG, China--(BUSINESS WIRE)--Shenyang Tonglian Group Co., Ltd. (‘Tonglian Group’ or the company), a company innovating and producing specialty pharmaceuticals including anti-infective treatments, today announces that the U.S. Food & Drug Administration (FDA) has approved a randomized, multicenter, placebo-controlled, double-blind clinical study of the safety and efficacy of Carrimycin for the treatment of severe COVID-19 in hospitalized patients.
AstraZeneca ($AZN) has made no secret of its intention to deepen its presence in China, despite the country's economic slowdown. And it's not above asking for local help to fulfill its objectives.nThe UK-based pharma group has enlisted the aid of Shenyang-based biopharma company 3SBio to help kick-start two drugs for diabetes. The disease already afflicts almost one in 10 adults in China and is becoming increasingly common as the population adopts a westernized lifestyle.